In blow to Jazz Pharma, US panel undoes clinical trial limits placed on Avadel
A Delaware federal judge went too far when enjoining Avadel CNS Pharmaceuticals from seeking regulatory approval of its sleep disorder drug Lumryz for the treatment of idiopathic hypersomnia, the US Court...To view the full article, register now.
Already a subscriber? Click here to view full article